These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9470806)

  • 1. Phase II study of semisynthetic paclitaxel in metastatic breast cancer.
    Hudis C; Riccio L; Holmes F; Seidman A; Baselga J; Currie V; Fennelly D; Gilewski T; Moynahan M; Raptis G; Sklarin N; Surbone A; Uhlenhopp M; Maickel N; Yao TJ; Hellmann S; Usakewicz J; Hortobagyi G; Norton L
    Eur J Cancer; 1997 Nov; 33(13):2198-202. PubMed ID: 9470806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
    D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
    Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy.
    Rivera E; Holmes FA; Frye D; Valero V; Theriault RL; Booser D; Walters R; Buzdar AU; Dhingra K; Fraschini G; Hortobagyi GN
    Cancer; 2000 Dec; 89(11):2195-201. PubMed ID: 11147589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
    Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
    J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy.
    Michael M; Bishop JF; Levi JA; Bell DR; Zalcberg JR; Friedlander ML; Olver IN; Smith JG; Toner GC
    Med J Aust; 1997 May; 166(10):520-3. PubMed ID: 9196484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
    Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J
    Breast Cancer Res Treat; 2008 Mar; 108(2):241-50. PubMed ID: 17476588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanded phase II trial of paclitaxel in metastatic breast cancer: a Southwest Oncology Group study.
    Geyer CE; Green SJ; Moinpour CM; O'Sullivan J; Goodwin DK; Canfield VA; Meyers FJ; Osborne CK; Martino S
    Breast Cancer Res Treat; 1998 Sep; 51(2):169-81. PubMed ID: 9879778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
    Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report.
    Akerley W; Sikov WM; Cummings F; Safran H; Strenger R; Marchant D
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-87-S17-90. PubMed ID: 9374102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of paclitaxel (Taxol) as first line treatment in advanced breast cancer.
    Swain SM; Honig SF; Tefft MC; Walton L
    Invest New Drugs; 1995; 13(3):217-22. PubMed ID: 8729949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.
    Gianni L; Munzone E; Capri G; Villani F; Spreafico C; Tarenzi E; Fulfaro F; Caraceni A; Martini C; Laffranchi A
    J Natl Cancer Inst; 1995 Aug; 87(15):1169-75. PubMed ID: 7674322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer.
    Perez EA; Vogel CL; Irwin DH; Kirshner JJ; Patel R
    J Clin Oncol; 2001 Nov; 19(22):4216-23. PubMed ID: 11709565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
    Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
    Seidman AD; Tiersten A; Hudis C; Gollub M; Barrett S; Yao TJ; Lepore J; Gilewski T; Currie V; Crown J
    J Clin Oncol; 1995 Oct; 13(10):2575-81. PubMed ID: 7595709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
    Giordano SH; Booser DJ; Murray JL; Ibrahim NK; Rahman ZU; Valero V; Theriault RL; Rosales MF; Rivera E; Frye D; Ewer M; Ordonez NG; Buzdar AU; Hortobagyi GN
    Clin Cancer Res; 2002 Nov; 8(11):3360-8. PubMed ID: 12429622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
    Trudeau ME; Eisenhauer EA; Higgins BP; Letendre F; Lofters WS; Norris BD; Vandenberg TA; Delorme F; Muldal AM
    J Clin Oncol; 1996 Feb; 14(2):422-8. PubMed ID: 8636752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.